Kidney Cancer Scotland
Cabo/atezo phase 3 combo RCC trial launched
The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma... Read More
Biomarker combo may help predict mRCC immuno response
When deciding on the best course of treatment for patients with metastatic renal cell carcinoma (mRCC), it’s difficult for oncologists to know... Read More
